In OHTN follow-up, how long after starting a medication for elevated intraocular pressure should the patient typically return for re-evaluation?

Prepare for the NBEO Part III Test with detailed quizzes on patient encounters and performance skills. Access flashcards and questions with explanations to enhance your study strategy. Perfect your skills for exam success!

Multiple Choice

In OHTN follow-up, how long after starting a medication for elevated intraocular pressure should the patient typically return for re-evaluation?

Explanation:
When you start a medication to lower intraocular pressure, you want to confirm how well it’s working and how the patient tolerates it fairly soon after beginning treatment. Most topical IOP-lowering meds show a meaningful effect within about a month, so rechecking around four weeks allows you to see the true response, verify that the target pressure is being approached, and assess adherence and any side effects. If the reduction is insufficient or there are tolerability issues, you can adjust the regimen promptly. Waiting only a week might miss the full effect, and delaying re-evaluation for several months or a year risks ongoing elevated IOP or adverse effects without timely management.

When you start a medication to lower intraocular pressure, you want to confirm how well it’s working and how the patient tolerates it fairly soon after beginning treatment. Most topical IOP-lowering meds show a meaningful effect within about a month, so rechecking around four weeks allows you to see the true response, verify that the target pressure is being approached, and assess adherence and any side effects. If the reduction is insufficient or there are tolerability issues, you can adjust the regimen promptly. Waiting only a week might miss the full effect, and delaying re-evaluation for several months or a year risks ongoing elevated IOP or adverse effects without timely management.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy